BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 29500652)

  • 1. 18F-FDG PET/CT in splenic marginal zone lymphoma.
    Albano D; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2018 Oct; 43(10):2721-2727. PubMed ID: 29500652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
    Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of
    Albano D; Camoni L; Giubbini R; Bertagna F
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e897-e904. PubMed ID: 32703751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation.
    Albano D; Bosio G; Giubbini R; Bertagna F
    Leuk Lymphoma; 2017 Oct; 58(10):2328-2334. PubMed ID: 28270020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary mucosa-associated lymphoid tissue lymphoma:
    Albano D; Borghesi A; Bosio G; Bertoli M; Maroldi R; Giubbini R; Bertagna F
    Br J Radiol; 2017 Nov; 90(1079):20170311. PubMed ID: 28830222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
    Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between
    Zhao J; Wang H
    J Med Imaging Radiat Oncol; 2021 Apr; 65(2):188-194. PubMed ID: 33538120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT and primary hepatic MALT: a case series.
    Albano D; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2016 Oct; 41(10):1956-9. PubMed ID: 27259334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric presentation of splenic marginal zone lymphoma on FDG PET/CT scan.
    Rezaee A; Zhao XF; Dilsizian V; Chen W
    Clin Nucl Med; 2014 Feb; 39(2):178-80. PubMed ID: 23640226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
    Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
    Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy.
    Zanoni L; Varani S; Attard L; Morigi JJ; Vanino E; Ortalli M; Fonti C; Viale P; Re MC; Fanti S; Ambrosini V
    Ann Nucl Med; 2019 Sep; 33(9):716-723. PubMed ID: 31254270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study.
    Kagan KBT; Guz D; Buchrits S; Gurion R; Vaxman I; Priss M; Groshar D; Catalano OA; Sherban A; Raanani P; Gafter-Gvili A; Bernstine H
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2290-2299. PubMed ID: 35079846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of
    Wang W; Ni X; Tang T; Wang J; Li Y; Song X
    Br J Radiol; 2022 Feb; 95(1130):20210635. PubMed ID: 34919440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
    Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal index for detecting splenic involvement on 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in diffuse large B-cell lymphoma.
    Kozuki R; Sugimoto T; Goto H; Miyamoto N; Hirakawa Y; Umeno A; Idei M; Tagawa S; Namba F; Tani R; Ohmori M; Hamanaka A; Adachi S; Tomita M
    Medicine (Baltimore); 2024 Mar; 103(9):e37290. PubMed ID: 38428864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.